Production and Characterization of Antipeptide Kallikrein 4 Antibodies: Use of Computer Modeling to Design Peptides Specific to
To date, prostate-specific antigen (PSA) has proven to be the most useful tumor marker for prostate cancer (1 –3 ). However, the PSA test does not discriminate well between men with benign disease and early prostate cancer, and it does not discriminate between aggressive and slow-growing cancers (4 ,5 ). Although a useful additional discriminator (5 ), the advent of free/total PSA assays has not significantly improved this outcome. Thus, an inability to make an early diagnosis has led to the increased burden of metastatic disease, and many patients are overtreated because clinically aggressive disease cannot be distinguished from clinically insignificant disease.
- Immunohistochemistry of p53, Bcl-2, and Ki-67 as Predictors of Chemosensitivity
- Anchorage-Independent Growth of Prostate Cancer Stem Cells
- Isolation of Circulating MicroRNAs from Microvesicles Found in Human Plasma
- Methods for the Study of Protein-Protein Interactions in Cancer Cell Biology
- Genetically Modified Clostridium for Gene Therapy of Tumors
- Array-Based Comparative Genomic Hybridization as a Tool for Analyzing the Leukemia Genome
- Detection of t(2;5)(p23;q35)Translocation by Long-Range PCR of Genomic DNA
- Construction of P450-Expressing Tumor Cell Lines Using Retroviruses
- Transfection and DNA-Mediated Gene Transfer
- 抑制癌细胞生长和血管生成的合成抗体“出世”